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Advances in genomics often lead healthcare professionals (HCPs) to learn new information, e.g., about
reinterpreted variants that could have clinical signiﬁcance for patients seen previously. A question arises
of whether HCPs should recontact these former patients. We present some ﬁndings interrogating the
views of patients (or parents of patients) with a rare or undiagnosed condition about how such recon-
tacting might be organised ethically and practically. Forty-one interviews were analysed thematically.
Participants suggested a 'joint venture' model in which efforts to recontact are shared with HCPs. Some
proposed an ICT-approach involving an electronic health record that automatically alerts them to
potentially relevant updates. The need for rigorous privacy controls and transparency about who could
access their data was emphasised. Importantly, these ﬁndings highlight that the lack of clarity about
recontacting is a symptom of a wider problem: the lack of necessary infrastructure to pool genomic data
responsibly, to aggregate it with other health data, and to enable patients/parents to receive updates. We
hope that our ﬁndings will instigate a debate about the way responsibilities for recontacting under any
joint venture model could be allocated, as well as the limitations and normative implications of using ICT
as a solution to this intractable problem. As a ﬁrst step to delineating responsibilities in the clinical
setting, we suggest HCPs should routinely discuss recontacting with patients/parents, including the new
information that should trigger a HCP to initiate recontact, as part of the consent process for genetic
testing.
© 2017 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Advances in genomics can lead healthcare professionals (HCPs)
to realise that they hold clinically relevant information about pa-
tients seen in clinic previously. This information might pertain to a
reinterpreted variant; a new test; or knowledge about treatment
and surveillance. Do HCPs have a duty or obligation to recontact the
former patients (or parents thereof)? What ought to be the natureom AB 203, MP 801, Univer-
ital, South Academic Block,
a).
Masson SAS. This is an open acceof this duty? What should trigger action to fulﬁl the duty? Fig. 1
illustrates an example of one potential trigger.
There is little empirical evidence and no formal guidance about
recontacting and no legally deﬁned duty to recontact: a HCP has a
legal duty of care to a patient, but might consider this to lapse once
they discharge the patient from their service. Nonetheless, legal
scholars have expressed concerns that deciding not to recontact
could amount to negligence (Pelias, 1991, 1992; Hunter et al., 2001;
Grifﬁn et al., 2007; O'Connor, 2014). At the same time, recontacting
could be perceived as a violation of privacy (Letendre and Godard,
2004). Legal arguments aside, Otten et al. (2014). have questioned
whether there is an ethical duty to recontact and have presented
several arguments in favour: beneﬁcence, in that information hasss article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. An example of recontacting.
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Metcalfe, 2008; O'Connor, 2014), and enhancement of autonomy
through offering information upon which the patient can act
(Hunter et al., 2001; Hastings et al., 2012; Clayton et al., 2013). A
counter-argument, however, is that patients cannot make an
autonomous decision about whether they would want to be
recontacted because they do not knowwhat information there is to
know. As well as a perceived invasion of privacy, being recontacted
could cause distress and lead to discrimination (Andrews, 1992;
Sharpe, 1999; Brown et al., 2006; Peshkin and Burke, 2007; Shirts
and Parker, 2008; Pyeritz, 2011). For example, Chen et al. found
that when HCPs recontacted patients/parents to say that their in-
formation would be used in a new research study, it caused
confusion and sometimes even anger, e.g., where parents initially
misunderstood and thought a diagnosis had been found (Chen
et al., 2017). These concerns might be outweighed by the beneﬁt
of being alerted to a potential risk amenable to intervention
(Hunter et al., 2001; Sexton and Metcalfe, 2008; Andrews, 1992;
Sexton et al., 2008).
Few empirical studies exist about recontacting: those reviewed
by Otten et al. (2014). did not explore the topic speciﬁcally.
Recently, we conducted the ﬁrst study to survey current recon-
tacting practices in UK clinical genetics services (Carrieri et al.,
2016), which revealed that genetic HCPs recontact patients/par-
ents in an ad hoc way and would recontact them with information
of potential clinical signiﬁcance, even if they had said they did not
want to be recontacted. Our follow up paper exploring the views of
a sample of UK genetic HCPs showed that they perceive several
practical barriers to recontacting: there is insufﬁcient money, staff,
and infrastructure, and no good way to track patients and relevant
information over time (Carrieri et al., 2017a). These ﬁndings sup-
port those from previous research (Ali-Khan et al., 2009; Murray
et al., 2011; Mulla, 2015). Arguably, however, HCPs might struggle
to deﬁne their responsibilities, and the limits thereof, even with
limitless resources.
Uncertainty thus remains about what form recontacting should
take: should it be entirely patient-led, whereby the patient/parent
routinely checks for updates? Or should it be a HCP-led model,
whereby HCPs routinely recontact former patients? If so, which
HCPs should recontact? Managing genetic information might be
new territory for non-specialist HCPsdwould they know how
(best) to act on new information? Some HCPs in our study (Carrieri
et al., 2017a) argued that decision-making about whether recon-
tacting happens, and efforts to make it happen, should be shared
between HCPs and patients/parents. For example, HCPs could invitepatients/parents to contact them at regular intervals, which would
trigger a check for updates. To an extent, this option could
circumvent limitations of resources and could give patients/parents
some choice about learning new information and thus respect their
preferences. Other HCPs argued that patients/parents would not
always have the understanding, organisational skills, or time to
recontact and that their decisions not to request updates would
sometimes be uninformed, so placing responsibility on themwould
be practically and ethically problematic. It is unclear what patients'/
parents’ views are about recontacting. This paper explores their
views, speciﬁcally about the way recontacting might be organised
in an ethically sound and practical way.
2. Methods
2.1. Sampling and recruitment
We purposefully sampled participants from four regional ge-
netics services serving a combined population of ~8 million. Local
collaborators at each site sent out study information and interested
parties contacted the researchers directly. We did not ask collabo-
rators to record the number of patients they contacted, so we are
unaware of our response rate. We also posted information on on-
line condition-speciﬁc support groups. Participants were 41 pa-
tients or parents thereof. Conditions were self-reported: 18 had a
condition that was rare (e.g. myotubular myopathy) or undiag-
nosed; 11 had a suspected hereditary cancer or cardiac condition
for which the genetic basis had not been found (e.g. BRCA1/2-
negative breast cancer, or a variant of uncertain signiﬁcance); and
12 had a diagnosis that was clearer (e.g., hereditary breast cancer or
Fragile X). All were potentially 'eligible' for being recontac-
teddeither for a test, a variant reclassiﬁcation, or because a newly
identiﬁed risk-reducing intervention was available. Four had been
recontacted by the genetics service, who offered the patient a test
where one was previously unavailable. Table 1 contains more
detail.
2.2. Data collection and analysis
We designed an interview schedule (based on our research
questions and empirical and conceptual literature) comprising
non-leading questions that were general and open-ended. We ar-
ranged a suitable time, date, and, for face-to-face interviews,
location. This was somewhere the participant could speak with us
undisturbed to keep discussions as conﬁdential as possible. We
piloted the interview schedule in our earlier interviews, after which
we reformulated potentially directive and complicated questions.
Dheensa, Carrieri, and Doheny conducted all interviews and had
regular team meetings and data analysis sessions to ensure that
there was consistency across our approaches. Analysis was the-
matic and was underpinned by aspects of grounded theory meth-
odology, such as constant comparison (Corbin and Strauss, 2015).
Data collection and analysis were iterative, thus we were able to
identify new and important questions and areas of ambiguity or
tentativeness in the analysis that were then explored in subsequent
interviews. The wider team oversaw, discussed, and compared
analyses to enhance reliability and rigour. We ceased data collec-
tion once we approached saturation of the emerging themes.
3. Results
The four main themes touch upon the overlapping questions of
to whom the responsibilities for recontacting belong and the
challenges of operationalising different responsibilities, e.g., via ICT
infrastructure. The themes, which mirror the participants' lines of
Table 1
Participants’ clinical proﬁles.
Identiﬁer Diagnosis Recontacted in a clinical setting? (i.e. contacted with new information or a new test
after being discharged)
1 Hereditary breast cancer (BRCA2)
2 Hereditary breast cancer (BRCA2)
3 Possibly hereditary breast cancer (tested negative for BRCA1 and BRCA2)
4 Possibly hereditary bowel cancer (tested negative for Lynch syndrome
associated genes)
5 Possibly hereditary breast cancer (tested negative for BRCA1 and BRCA2)
6 Carrier of BRCA gene and parent of child with hereditary breast cancer Yes e recontacted for genetic test when one was unavailable before
7 Possibly hereditary breast cancer (tested negative for BRCA1 and BRCA2)
8 X-linked myotubular myopathy Yes - recontacted for genetic test when one was unavailable before
9 Parent of children with possible mosaic trisomy 16
10e11 Parents of children with undiagnosed microdeletion syndrome
12 Parent of children with undiagnosed microdeletion syndrome
13e14 Parents of child with chromosome 17 duplication
15 Fragile X
16 Fragile X
17 Parent of child with undiagnosed chromosome disorder
18 Familial hypercholesterolemia
19 Familial hypercholesterolemia
20 X-linked myotubular myopathy Yes - recontacted for genetic test when one was unavailable before
21 Parent of deceased child with Xq28 duplication
22 Parent of child with brachytelephalangic chondrodysplasia punctata
23 Possibly hereditary cardiomyopathy
24e25 Parents of child with PCDH19 epilepsy
26e27 Parents of undiagnosed child
28 Possibly hereditary hypertrophic cardiomyopathy (tested negative for
main genes)
29 Parent of child with 1q21.1 microdeletion
30 Parent of undiagnosed child
31 Parent of child with undiagnosed microdeletion syndrome
32 Autosomal recessive Alport syndrome and parent of a child with Alport Yes - recontacted for genetic test when one was unavailable before
33 Hereditary breast cancer (BRCA1)
34 Possibly hereditary breast cancer (variant of unknown signiﬁcance)
35 Hereditary hypertrophic obstructive cardiomyopathy
36 Possibly hereditary breast cancer (variant of unknown signiﬁcance)
37 Possibly hereditary ovarian cancer (variant of unknown signiﬁcance)
38 Possibly hereditary breast cancer (variant of unknown signiﬁcance)
39 Lynch syndrome
40 Possibly hereditary arrhythmogenic right ventricular cardiomyopathy
(ARVC)
41 Possibly hereditary breast cancer (tested negative for BRCA1 and BRCA2)
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tients/parents; (2) recontacting ought to be a ‘joint venture’; (3)
improved technical infrastructure is needed to operationalise any
joint venture; and (4) difﬁculties remain around deﬁning and
allocating responsibilities.3.1. Recontacting should not be driven solely by patients/parents
Almost all participants thought that recontacting ought to
happen for 'signiﬁcant' information (that which could lead to, or
shed light on, the meaning of a diagnosis, or which could change
treatment). However, as the quotations below emphasise, they did
not think patients/parents could always be expected to instigate
recontact. They would not know where to look for, or how to
interpret, information that might help them spot signiﬁcant
changes, and even if they did look for it, there was a dearth of good
quality information available;
P5: “[Patients are] not going to be able to ﬁnd it on their own. So
somebody has to be responsible for making that happen”.
P18: “[HCPs] knowwhat they're looking at, whereas I could read
something online andmisinterpret it. And if you're theworrying
type, you could start to worry about things.”Availability and searchability of information aside, participants
argued that patients/parents would not always have the conﬁdence
to ask their HCPs whether potentially relevant information they
had seen was indeed relevant and they would not always know
who to contact and how. Indeed, several participants were,
“confused about who is responsible … for care or screening” (P39).
Some had even sought updates after being invited to do so, but
could not get through to anyone who could help them. Participants
also pointed out that patients/parents might ﬁnd seeking infor-
mation distressing and that it could lead them to “dwell” on their
condition;
P33: “It would be nicer if it wasn't the patient that had to do that
sort of thing. It keeps you in that cancer mentality and I don't
feel that's part of my life anymore.”
By contrast, a few participants argued that everybody ought to
take responsibility over their own health and that there are insuf-
ﬁcient resources to force reluctant patients/parents to engage with
seeking information;
P41: “Government-information has to be accessible, but it's not
someone else's responsibility to feed it to me. I'm an individual
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They need to disseminate it and I need to read it [and] act on it”.
Underpinning all of these issues was a concern that recontact-
ing, if left entirely to patients/parents, could result in harm, such as
them not acting upon information that was relevant to them. Par-
ticipants perceived this as a harm that could be avoided through
HCPs’ input.3.2. Recontacting ought to be a ‘joint venture’
Leading on from the ﬁnding that participants did not think pa-
tients/parents ought to be the main drivers of recontacting, some
participants thought HCPs had a “duty to contact … if they ﬁnd
something out” [P22], in part because working for the UK National
Health Service (NHS) gave them unique access to data, as well as
the knowledge of what information would merit recontact;
P37: “The NHS is probably in pole position for collating this in-
formation. I don't knowwho could be responsible in theway the
NHS is.”
P30: “You [parent] are probably a good investigator and [can]
look into the bits that are speciﬁc [to you], but professionals
have access to tools that we don't, that give them information
that we would never have access to.”
For the most part, participants did not argue that the health
service should be solely responsible for recontacting, but that
recontacting should be a “joint venture” (P37) between patients/
parents and professionals. These participants argued for this
approach not because, as existing literature suggests, it would be
more protective of autonomy and choice about whether to receive
information (rather, participants were keen to receive information)
but because this model was the only one perceived as practically
feasible given the resource constraints in the health service. In fact,
many participants thought it would be difﬁcult for the health ser-
vice to assign any resources to recontacting, because of the pressure
on HCPs to see newly referred patients. Some thought NHS staff
ought to continue prioritising care for the unwell and public health,
and were resigned to thinking it impossible for them to also offer
recontact services;
P34: “With obesity, diabetes et cetera, do I think it's realistic that
there's going to be additional funding for this? I don't think
that's going to happen. Other things are more impacting and
could do with more energy and research. In an ideal world, yes
of course. In reality, I think it's unlikely.”
Interestingly, some participants considered the health service's
resource-constraints to be an inadequate justiﬁcation for jet-
tisoning its responsibility to keep patients/parents informed;
P30: “Professionals now, they're given more and more re-
sponsibility, more area of people to cover, still the amount of
time to do that, and a reduced budget. I understand why [they
don't recontact], but it doesn't make it any easier for us to
accept”.3.3. Improved technical infrastructure is needed to operationalise
any joint venture
Participants discussed the limited capacity for recontactinggiven the currently available infrastructure:
P5: “It almost comes before the question about should you
contact people … you need a mechanism to highlight the in-
formation ﬁrst before that can happen.”
P26: “We go to appointments and we're asked things about
[child]. It's all in his notes [but] because he's got ﬁve stacks of
notes, you think, ‘No one ever reads those.’ If even the notes
can't get sorted, and they [i.e. the different HCPs involved in his
care] are asking [us] the same questions, how is someone going
to remember in six months' time to phone us up or send a letter,
unless there's a foolproof system in place and it says, ‘This child
has got this’, and there's something that prompts them [to
contact us]?”
As illustrated, they argued that having a mechanism in place
that would enable recontacting preceded the question about
whether HCPs had, or could act on, any duty to recontact. Indeed,
several participants suggested that the operationalisation of a ‘joint
venture’ model of recontacting required a vastly improved ICT-
system.
While participants' ideas about this system were not well-
deﬁned, a main feature was that they should have access to an
electronic health record (EHR) that could automatically alert them
when there was new information available, such as a reclassiﬁed
variant in a genome database;
P29: “Working in IT., I can't see any reason there can't be some
sort of database when they ﬁnd some new bit of research and
this database is updated, from the medical [world] to people. So
that [database] can be updated, sends you an email [or] letter,
however you want, and you can read it and go back to your
consultant if you want to discuss.”
Crucially, some also argued that the health service needed better
infrastructure for communication between HCPs, as well as be-
tween HCPs and patients/parents, and that this was needed for
providing joined-up care for multi-system disorders, and not just
for recontacting;
P26: “You might have somebody who looks after hearts or looks
after lungs, but the body all works in sequence together. They all
have to talk.”
Some participants mentioned previous expensive ICT failures in
the NHS, and suggested that a system had not been set up because
it would be “a massive cultural change… [which] by the time they've
started to implement, is already out of date” [P26]. Others pointed out
that improving infrastructure might not be difﬁcult, because the
data already existed: it would simply involve better integration and
curation and for HCPs to use the data more efﬁciently;
P30: “The [health service has] a lot of centralised database
sharing, so I can't see that it would be too difﬁcult to obtain and
return information that's relevant to you … Various different
people and users can have different levels of access … [It]
wouldn't be difﬁcult to set up searching criteria. Databases are
fast, so it would only take seconds to come back with
information.”
They argued that such infrastructure would enable patients/
parents to get some information without waiting a “long period to
get a genetics appointment” (P21), that it would be “money well
spent” [P24] and that it could ultimately save the health service
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vestigations already done [P20], improve efﬁciency and commu-
nication between HCPs and patients/parents, and improve rates of
diagnosis and screening. This could in turn reduce hospital stays
[P24] and reduce litigation against the health service [P26]. They
perceived the potential beneﬁts and cost-savings as particularly
great in the genomic setting because;
P31: “It's both parents, extended family. So it could save the NHS
thousands. It costs lots of money [for the NHS] to input the data
to start with, but I can see exponentially it would be better in the
long run”.
From participants' perspectives, increased efﬁciency could
enable even those patients/parents whose hospital trusts were
understaffed to be recontacted, thus enhancing fairness in treat-
ment across the country. They contended that investing in such
infrastructure would help to build trust in the health service
because patients/parents would be reassured that it was using the
best possible tools for diagnosis [P41]. By enabling ongoing contact
and recontact, infrastructure could also make it more possible for
patients/parents to receive support from the health service. P31,
who had seen the genetics service once when her (now adult) son
was ﬁrst noticed to have autism, highlighted a desire for such
support;
P31: “Nobody's ever put any input into it; it's just, ‘go away and
get on with it’. They give you this, ‘he has this wrong, but we
don't know what it means, but we don't want to see you again’.
And that's quite frightening. There is the element of support
within information.”
Importantly, some participants expressed concern about who
would have access to their data and stressed the need for trans-
parency and rigorously-controlled access to protect their privacy;
P23: “I wouldn't wantmy particular medical details going to just
anybody”.
P26: “I'd like to knowwho's been looking at my records, because
you hear and see of people who work in the NHS and they're
looking at other people's records which aren't relevant to them.
The trust thing, that when you give information e and it's quite
personal, your health information e you want to choose who
you share it with, unless obviously something you've got is a risk
to the rest of society. [It’s important] that you can control that
data.”
Participants thought that seeingwho had accessed their records,
and seeing that only 'relevant' people could do so, would enhance
transparency and build trustworthiness. However, in the above
quotation, P26 points to a bigger question about how control over
data privacy balances with, or potentially hinders, the ‘openness’ of
data required for care and investigation. Another bigger question
waswhether and how any updates about research studies could and
should be integrated into records used in clinic, with some partic-
ipants thinking EHRs could integrate research ﬁndings via the
process described.3.4. Difﬁculties remain around deﬁning and allocating
responsibilities
Participants thought that, under a ‘joint venture’ model, there
would remain difﬁculties deﬁning and allocating responsibility. For
example, P29 was unsure at what point a HCPs' duty to recontactpatients/parents was discharged;
P29: “90% of me says, once you've been told something, like go
and get your ﬂu jab, if you don't follow it up, if you get ﬂu and
die it's your fault. But 10% of me says the NHS has a duty of care
… but you can keep going back to the funding, there's only so
much they can do. Once it's been sent out and they've been told
there's new information there, that's almost enough. But that
becomes difﬁcult. I'm thinking aloud.”
Potential inaction by patients/parents was another issue. P34 for
example pointed out that “big and very certain” public health
messages “are ignored by most people”, raising questions about how
the “NHS marshals its extremely limited resources”. That is, she
questioned whether any resources spent on recontacting would
indeed be “well-spent”, as P24 claimed.
A few others thought that compared with the public health
setting, the availability of speciﬁc information to speciﬁc patients in
the genetic setting would both augment HCPs' duty and make the
dissemination of information more worthwhile, and that targeting
messages might make inaction less likely. Yet, participants also
gave examples of where they had not acted on information HCPs
had given themde.g., because they did not take advice “religiously”
[P21] or because they felt contacting HCPs would be “silly …
[because they felt] perfectly well, [which did not warrant] making a
fuss” [P39]. Given that there were so many perceived difﬁculties
that could thwart any resulting beneﬁt from a recontactdfrom
practical issues (e.g., parents/patients not checking their EHR), to
psychosocial issues (e.g. coping by avoiding information), to limited
comprehension (e.g., misunderstanding the information), a con-
ceptual question remained, and underpinned participants'
thinking, aboutwhether a HCPs’ dutywould be discharged once the
EHRwas updated, and how far HCPs should go to ensure the patient
comes to clinic. Practical barriers might be more easily addressed,
but others, such as patients/parents not thinking the information
important or relevant, could be less easy to overcome.
4. Discussion
This study has explored patients/parents' views about how
recontacting might be organised ethically and practically in clinical
genetic practice. A key ﬁnding was that most participants consid-
ered recontacting important and desirable, but that resource con-
straints in the UK's health service would make it difﬁcult or
impossible for HCPs to recontact patients/parents. Thus, they
thought any model of recontacting would have to be a joint ven-
ture, whereby patients/parents and HCPs share the efforts involved.
To an extent, our ﬁndings echo those from a study by Townsend
et al. (2012), in which participants (HCPs, parents of children who
had undergone genetic testing, andmembers of the public) thought
that patients/parents were responsible for contacting HCPs to
check for genomic developments. While HCPs thought so for rea-
sons to do with the practicality of recontacting, members of the
public and parents' reasons were about having a choice over
whether to learn about new developments. In our study, the ma-
jority of participants were in favour of receiving new information,
so the desire for choice in this regard did not materialise. Impor-
tantly, however, they maintained that the joint venture model
would be in line with the idea that individuals ought to take re-
sponsibility for maintaining and promoting their own, or their
children's, health. Our ﬁndings reﬂects a wider movement in the
western developed economies of increasing patient involvement in
healthcare and, more broadly, the move towards ‘shared decision-
making’ in the UK health service (Coulter and Collins, 2011). The
ﬁndings also align with our recent recommendation advocating a
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routinely discuss recontacting with patients/parents, including is-
sues that might trigger it, in the context of consent for genetic
testing (Carrieri et al., 2017b). Joint ventures between HCPs and
patients have been proposed in other contexts of clinical genetics,
for example by Wouters et al. (2016) regarding whether HCPs or
patients are responsible for disseminating genetic information to at
risk relatives and by Mackley et al. (2017) regarding disclosure of
secondary ﬁndings.
Participants suggested that a way the joint venture model could
be operationalised was via an EHR that centralises their informa-
tion from across different services and automatically alerts them
when there is new information available, e.g., when a genome
database is updated and a variant is reclassiﬁed. Extrapolating from
our participants' descriptions, the work involved in the process of
recontacting would then be shared in that professionals (lab sci-
entists, researchers, and possibly HCPs) would update genome
databases, patients/parents would check their EHR and respond to
the resultant alert, and HCPs would discuss the new information
with the patient/parent to assess its relevance. This ﬁnding high-
lights a key issue, which is that the lack of clarity about recontacting
is a symptom of a wider problem: the deﬁciency of necessary
infrastructure to (i) pool and curate high-quality, harmonised
genomic data, (ii) to link this data to other quality health data, (iii)
to make this data available to HCPs involved in care, and (iv) to
enable patients/parents to receive updatesdand importantly to do
so in a responsible and trustworthy way, that respects privacy and
conﬁdentiality. Currently, the absence of a global variant-calling
database would be a barrier to implementing the optimal version
of a system described by our participants, although groups such as
the Global Alliance for Genomic Health are working to improve
these processes (Siu et al., 2016). The American College of Medical
Genetics and Genomics (ACMG) recently released a position
statement advocating the “extensive sharing of laboratory and
clinical data”, on the basis that sharing can improve care, research,
and web-based decision support tools, and can offer ﬁnancial
beneﬁt, such as reducing the duplication of unpublished but
resolved pharmaceutical research. They argue that data sharing can
be compatible with protection of privacy and that sharing systems
should be secure and “provide transparency in the documentation
of data sharing transactions” (ACMG Board of Directors (2017)). Our
ﬁndings emphasise the importance of this: participants under-
scored the importance of privacy, as well as transparency and
control over who could access data and for what purpose. We note
the argument of Prainsack (2017) here, that the term ‘sharing’ is
best avoided in the context of genomic data because it is too broad
and has inappropriately moralistic undertonesdwe have used it
here, albeit with reservations, because it has gained traction in the
debates.
Further research and thinking is required around the enormous
challenge of translating aggregate genomic data into alerts in in-
dividual EHRs. As well as the technical problem of how best to
integrate different ICT infrastructures, challenges would arise for
laboratory scientists, researchers, and possibly HCPs interpreting
the data and deciding to which 'types' of patients the information
would be relevant. They would then need to decide how to inform
patients/parents (for example, in what format to provide the in-
formation and whether decision aids would be helpful) to enable
patients/parents to make meaningful choices. Increasing the
availability of up-to-date and secure genomics databases and EHRs
is only part of the challenge.
More broadly, the use of EHRs raises ethical issues. While claims
have been made that they can empower patients (Giardina et al.,
2014), they also pose a risk to privacydmembers of a patient's
family or even employers or insurers could access records withoutthe patient's consent or knowledge (Wynia and Dunn, 2010). The
implications of this could be ampliﬁed where the EHR includes
genetic information, because this information is often thought of as
particularly sensitive, as it can be predictive and relevant to family
members. For this reason, clinical genetics notes are usually sepa-
rate from a patient's medical record. Some patients/parents might
also perceive the receipt of an alert as being in violation of their
right, or interest, not to know the information, particularly in ju-
risdictions where the law speciﬁcally protects this right (German
Genetic Diagnosis Act). Given these issues, we would agree with
Shoenbill et al. (2014), who think HCPs should discuss the potential
integration of genetic information into a EHR in the consent process
and in any post-test counseling with patients/parents. We also
argue that patients/parents should have the option of opting-out of
receiving alerts about new information, as well as the opportunity
to opt back in easily at any time, or after a certain period.
An overarching issue about any ICT-based solution is the risk of
introducing inequity: disadvantage to the less ICT-savvy and/or
those whose lives render themdfor social, economic, or other
reasonsdless able to engage effectively with the process of
recontacting. HCPs would end up seeing and reinterpreting infor-
mation for patients/parents who do respond to automatic updates,
leaving less time for actively engaging with the less responsive, and
potentially needier, patients. This reﬂects Tudor Hart's inverse care
law (Tudor, 1971): those who need healthcare less will use it more,
while those whose needs are greater will not engage as effectively,
and in turn, their needs will be relatively neglected. Any solution
that puts some responsibility to act on patients/parents might lead
to inequity, but one that uses ICT might make the divide greater.
5. Conclusion
This paper has shown support for a joint venture model of
recontacting. Questions regarding this model, whether oper-
ationalised via ICT or otherwise, need to be addressed urgently, and
of course the proposed ‘solutions’ offered heremay generate ethical
as well as practical difﬁculties. One consideration is what infor-
mation a HCP should contact a patient/parent with in the ﬁrst
instance: should they send a general notice that there are new
developments or information that is more speciﬁc? The more un-
wieldy questions include, when is the HCPs' duty dischargedwithin
this shared model? How would one know when the practice of
recontacting has been sub-optimal and what possible forms of re-
dress (e.g. claims of negligence) are available? How can recon-
tacting be implemented without exacerbating pre-existing health
inequalities? We need further debate about the limitations and
normative implications of using ICT infrastructure as a solution to
this intractable problem. This paper is intended to instigate such
debate.
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